Descrizione del progetto
Sperimentazioni cliniche in programma per il nuovo rivoluzionario farmaco per il PTSD
Il disturbo post-traumatico da stress (PTSD) è una condizione mentale debilitante, in cui i pazienti rivivono esperienze traumatiche attraverso flashback, pensieri intrusivi, incubi e grave ansia. Trenta milioni di persone soffrono di PTSD nell’UE e negli Stati Uniti e il 70 % non riesce a trovare sollievo. Il progetto TWO-BIRDS sta conducendo uno studio di fattibilità sul SYT-510, promettente candidato preclinico a farmaco, parte di una nuova classe di farmaci per il trattamento del PTSD detti inibitori selettivi del reuptake degli endocannabinoidi (SERI). I SERI regolano il sistema endocannabinoide (altamente disregolato nel PTSD), ripristinando l’equilibrio della chimica del cervello senza rischio di dipendenza da farmaci o disfunzione cognitiva. TWO-BIRDS mira a sviluppare un piano dettagliato per le attività precliniche, cliniche e normative finali per SYT-510 e creare un piano aziendale per i potenziali investitori.
Obiettivo
PTSD affects over 15 million people in Europe. So far, 70% never find relief. New drugs that restore the endocannabinoid (endoCx) neural circuit hold potential to change this paradigm.
Post-traumatic stress disorder, known as PTSD, is one of the most unforgiving psychological disorders. As victims of trauma, PTSD patients are coerced by their dysregulated brain chemistries to relive their traumatic experiences, where specific triggers provoke symptoms such as flashbacks, intrusive thoughts, nightmares and severe anxiety. Unfortunately, current drugs address only specific downstream neural circuits and are highly ineffective. The endoCx is highly dysregulated in PTSD, and as a 'master neuroregulator', drugs that restore its function in a safe and sustainable manner have strong potential to be the first effective treatment for PTSD.
Synendos is a pharmaceutical start-up who have identified a new family of drugs that modulate the endoCx via a new mechanism-of-action. Termed SERIs, or, ‘selective endocannabinoid reuptake inhibitors’, these small molecule drugs regulate the endoCx system in a self-limiting manner, thereby restoring balance to brain chemistry without risk of drug dependency or cognitive disrepair. Our lead compound SYT-510 is at the stage of preclinical development, where it has demonstrated effective anti-anxiety activity, favourable pharmacokinetic characteristics and a strong safety profile.
We aim to commercialize SYT-510 through establishing partnering deals with pharma companies for its co-development and eventual sales. With a patient population of over 30 million (in EU/US combined), PTSD is an attractive market for drug development.
TWO-BIRDS project: The main aims of this feasibility study are to 1) work to further understand clinician and patient needs, 2) define a detailed plan for final preclinical, clinical and regulatory activities and 3) consolidate new information into an investor-ready business plan.
Campo scientifico
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-1
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
4123 ALLSCHWIL
Svizzera
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.